- Previous Close
2.8500 - Open
2.8200 - Bid 2.1000 x 100
- Ask 3.6200 x 100
- Day's Range
2.7700 - 2.9200 - 52 Week Range
2.7500 - 4.1450 - Volume
238,415 - Avg. Volume
341,715 - Market Cap (intraday)
246.313M - Beta (5Y Monthly) 0.18
- PE Ratio (TTM)
-- - EPS (TTM)
-2.0000 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.07
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
ateapharma.comRecent News: AVIR
View MorePerformance Overview: AVIR
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVIR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVIR
View MoreValuation Measures
Market Cap
246.31M
Enterprise Value
-206.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.56
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.60%
Return on Equity (ttm)
-33.88%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-168.38M
Diluted EPS (ttm)
-2.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
454.72M
Total Debt/Equity (mrq)
0.37%
Levered Free Cash Flow (ttm)
-39.55M